ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.

Marth, ChristianVulsteke, ChristofPerez, Maria Jesus RubioMakker, VickyBraicu, Elena IoanaMcNeish, Iain A.Madry, RadoslawAyhan, AliHasegawa, KoseiWu, XiaohuaDutta, LeaXu, CindyKeefe, Stephen MichaelLee, John J.Pignata, Sandro2021-03-052021-03-0520200732-183Xhttp://hdl.handle.net/11727/5511enginfo:eu-repo/semantics/closedAccessENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.Conference Object3815000560368309198